U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


U.S. Pulls Back Proposed AI Chip Export Rule Amid Policy Uncertainty
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
New Zealand Tightens Immigration Laws to Combat Crime and Asylum Abuse
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
ICE Arrest of Guatemalan Woman at San Francisco Airport Sparks Outrage
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
O'Hare Flight Cuts: Chicago Pushes Back as FAA Weighs Summer Limits
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 



